Morristown, NJ – In a major healthcare fraud case, RDx Bioscience Inc., a Kenilworth-based clinical laboratory, along with its owner and CEO, Eric Leykin, have consented to a $13.25 million settlement over accusations of illegal kickbacks and unnecessary medical testing. U.S. Attorney Philip R. Sellinger announced the agreement, emphasizing the government’s commitment to combating healthcare fraud.
The settlement comprises $10.32 million to the federal government and an additional $2.93 million to the state of New Jersey. This resolution addresses allegations under the False Claims Act involving RDx’s financial schemes that purportedly influenced healthcare providers’ decisions and led to unnecessary testing at the expense of taxpayer dollars.
Source: NJ Lab and CEO to Pay Over $13M in Healthcare Fraud Settlement / Morristown Minute
RDx Bioscience Inc., a New Jersey-based clinical laboratory, and its owner/CEO Eric Leykin agreed to pay a $13.25 million settlement for alleged healthcare fraud.